Keros Therapeutics (KROS) catalysts

Upcoming FDA decisions and readouts we track for Keros Therapeutics, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 07 Oct 2026

FreeBioList tracks 1 upcoming catalyst for Keros Therapeutics (KROS, listed on Nasdaq). It concerns Rinvatercept (Duchenne muscular dystrophy).

First on the list: the Phase 2 readout for Rinvatercept (Duchenne muscular dystrophy), guided by the company to H1 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 07 Oct 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: KROS
Next catalyst: H1 2027
Type: Phase 2 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Keros Therapeutics KROS · Nasdaq	Rinvatercept	Duchenne muscular dystrophy	H1 2027 company guidance	Phase 2 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing headline: "Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD • Initial data expected in the first half of 2027". Source: 8-K exhibit 99.1, filed 28 Sep 2026 · verified 07 Oct 2026

Companies working on related conditions

Capricor Therapeutics (CAPR)Duchenne muscular dystrophy cardiomyopathy
Dyne Therapeutics (DYN)Duchenne muscular dystrophy, exon 51 skipping; Myotonic dystrophy type 1 (DM1)
BridgeBio Pharma (BBIO)Limb-girdle muscular dystrophy type 2I/R9; Autosomal dominant hypocalcaemia type 1 (ADH1)